BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 31824866)

  • 1. Development and Validation of an IDH1-Associated Immune Prognostic Signature for Diffuse Lower-Grade Glioma.
    Deng X; Lin D; Chen B; Zhang X; Xu X; Yang Z; Shen X; Yang L; Lu X; Sheng H; Yin B; Zhang N; Lin J
    Front Oncol; 2019; 9():1310. PubMed ID: 31824866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Model for Lower-Grade Glioma.
    Yin W; Jiang X; Tan J; Xin Z; Zhou Q; Zhan C; Fu X; Wu Z; Guo Y; Jiang Z; Ren C; Tang G
    Front Oncol; 2020; 10():1409. PubMed ID: 32974146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses.
    Cheng W; Ren X; Zhang C; Cai J; Han S; Wu A
    Mol Neurobiol; 2017 Oct; 54(8):5996-6005. PubMed ID: 27696222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
    Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
    Front Immunol; 2020; 11():603341. PubMed ID: 33363544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structuring and validating a prognostic model for low-grade gliomas based on the genes for plasma membrane tension.
    Li J; Lv F; Jin T
    Front Neurol; 2022; 13():1024869. PubMed ID: 36408514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and prognostic value of microRNAs in lower-grade glioma depends on IDH1/2 status.
    Cheng W; Ren X; Zhang C; Han S; Wu A
    J Neurooncol; 2017 Apr; 132(2):207-218. PubMed ID: 28091987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Prognostic Microenvironment-Related Immune Signature
    Qiu H; Li Y; Cheng S; Li J; He C; Li J
    Front Oncol; 2020; 10():580263. PubMed ID: 33425732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification, and Experimental and Bioinformatics Validation of an Immune-Related Prognosis Gene Signature for Low-Grade Glioma Based on mRNAsi.
    Wang Y; Ye S; Wu D; Xu Z; Wei W; Duan F; Luo M
    Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma.
    Zhang M; Wang X; Chen X; Zhang Q; Hong J
    Front Genet; 2020; 11():363. PubMed ID: 32351547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma.
    Dao Trong P; Rösch S; Mairbäurl H; Pusch S; Unterberg A; Herold-Mende C; Warta R
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Four-Gene Signature Associated With Immune Checkpoint for Predicting Prognosis in Lower-Grade Glioma.
    Xiao Y; Cui G; Ren X; Hao J; Zhang Y; Yang X; Wang Z; Zhu X; Wang H; Hao C; Duan H
    Front Oncol; 2020; 10():605737. PubMed ID: 33381460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A four-protein expression prognostic signature predicts clinical outcome of lower-grade glioma.
    Patil V; Mahalingam K
    Gene; 2018 Dec; 679():57-64. PubMed ID: 30077762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated analysis of inflammatory response subtype-related signature to predict clinical outcomes, immune status and drug targets in lower-grade glioma.
    Cao Y; Zhu H; Chen Q; Huang H; Xie D; Li X; Jiang X; Ren C; Peng J
    Front Pharmacol; 2022; 13():914667. PubMed ID: 36091778
    [No Abstract]   [Full Text] [Related]  

  • 15. RARRES2 is Downregulated in Isocitrate Dehydrogenase 1 Mutant Glioma Patients and Served as an Unfavorable Prognostic Factor of Glioma.
    Wang H; Wang X; Xu L; Zhang J
    World Neurosurg; 2023 Aug; 176():e610-e622. PubMed ID: 37271257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and validation of a 21-mRNA prognostic signature in diffuse lower-grade gliomas.
    Song LR; Weng JC; Huo XL; Wang L; Li H; Li D; Wu Z; Zhang JT
    J Neurooncol; 2020 Jan; 146(1):207-217. PubMed ID: 31853837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of ceRNA networks with different types of
    Wang WJ; Lu YJ; Li Y; Tang JQ; Wang H; Song W; Wang JJ; Huang YQ; Wang Y; Lian L
    Ann Transl Med; 2022 Mar; 10(5):254. PubMed ID: 35402587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Characterization of a Novel E3-Related Gene Signature With Implications in Prognosis and Immunotherapy of Low-Grade Gliomas.
    Tan S; Spear R; Zhao J; Sun X; Wang P
    Front Genet; 2022; 13():905047. PubMed ID: 35832194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Immune-Related Prognostic Signature for Predicting Clinical Outcomes and Immune Landscape in IDH-Mutant Lower-Grade Gliomas.
    Xiao G; Gao X; Li L; Liu C; Liu Z; Peng H; Xia X; Yi X; Zhou R
    J Oncol; 2021; 2021():3766685. PubMed ID: 34961815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of
    Huang SP; Chan YC; Huang SY; Lin YF
    Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31861486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.